Utility of atypical antipsychotics in the treatment of resistant unipolar depression

CNS Drugs

Volumn 23, Issue 5, 2009, Pages 369-377

  DeBattista, Charles ^a   Hawkins, Jessica ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CENTRAL STIMULANT AGENT; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; LITHIUM; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ADJUVANT THERAPY; AKATHISIA; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEART SIZE; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; METABOLIC DISORDER; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; HUMANS;

EID: 66249105682     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923050-00002     Document Type: Review

References (32)

1. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52 (1): 46-54
2. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004; 9 (11): 808-16, 818-21
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905-17
4. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163 (9): 1519-30; quiz 1665
5. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163 (7): 1161-72
6. DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006; 20 (3 Suppl.): 11-8
7. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2007; 20 (1): 23-9
8. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005; 66 Suppl. 8: 30-40
9. Möller HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 2005 Apr; 255 (2): 83-93
10. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008 Apr 16; (2): CD006722
11. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989 Jul; 50 (7): 241-9
12. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23 (3): 250-62
13. Ballas C, Yang C, O'Reardon J, et al. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4 (2): 179-86
14. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158(1): 131-4
15. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/ fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66 (10): 1289-97
16. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23 (6): 364-72
17. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind, comparision of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007 Feb; 68 (2): 224-36
18. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16 (4): 189-94
19. Ketter TA, Wang PW, Chandler RA, et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006; 18 (3): 169-72
20. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007 Jun; 68 (6): 843-53
21. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22 (1): 1-9
22. Sagud M, Mihaljević-Peles A, Mück-Seler D, et al. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology (Berl) 2006; 187 (4): 511-4
23. Mattingly GLH, Canale J, Anderson R. Quetiapine combination for treatment resistant depression. 159th Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
24. Doree JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007; 23 (2): 333-41
25. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatmentresistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31 (11): 2505-13
26. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65 (2): 217-21
27. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment resistant depression: a randomized, open label, pilot study. J Clin Psychiatry 2007; 68 (7): 1071-7
28. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64 (11): 1349-56
29. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008 Apr; 20 (2): 156-65
30. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007; 61 (5): 671-8
31. Barbee JG, Conrad EJ, Jambour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004 Jul; 65 (7): 975-81
32. Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008 Jan; 16 (1): 21-30